Feb 4 (Reuters) - Optimer Pharmaceuticals Inc:
* Says to file for priority review when filing NDA with FDA - conf call
* Says 'no color to add' on fidaxomicin partnership, talks going on
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Says to file for priority review when filing NDA with FDA - conf call
* Says 'no color to add' on fidaxomicin partnership, talks going on
((Bangalore Equities Newsroom; +91 80 4135 5800; within U.S. +1 646 223 8780)) (For more news, please click here) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.